What is the recommended management for a patient with chronic hepatitis B infection who has decompensated cirrhosis presenting with ascites, dyspnea, hypoalbuminemia, elevated international normalized ratio, and worsening renal function?

Management of Chronic Hepatitis B with Decompensated Cirrhosis

This patient requires immediate initiation of nucleos(t)ide analogue therapy with either entecavir or tenofovir, urgent evaluation for liver transplantation, and aggressive management of ascites and renal dysfunction. 1, 2

Immediate Antiviral Therapy

Start oral antiviral therapy immediately if HBV DNA is detectable by PCR, regardless of ALT level or HBV DNA quantity. 1, 2 The most recent 2022 KASL guidelines are unequivocal: in decompensated cirrhosis, nucleos(t)ide analogues should be initiated if serum HBV DNA is detected at any level, regardless of ALT 1.

Drug Selection

Monotherapy with either tenofovir or entecavir is the preferred first-line treatment due to their potent antiviral efficacy and high genetic barrier to resistance 2, 3.

• For decompensated cirrhosis specifically, use entecavir 1 mg daily (not the standard 0.5 mg dose used in compensated disease) 3
• Tenofovir is equally effective and can be used as an alternative 2
• Never use peginterferon-alfa in decompensated cirrhosis - it is absolutely contraindicated due to risk of hepatic failure and serious complications 1, 2

Critical Monitoring for Renal Function

Given this patient's increasing creatinine trend, monitor renal function closely before and during therapy 3. Both entecavir and tenofovir require dose adjustments based on creatinine clearance 2. Check blood urea nitrogen and creatinine every 1-3 months, particularly with tenofovir use 4.

Ascites Management

This patient's increasing abdominal girth indicates significant ascites requiring immediate intervention:

Diagnostic Paracentesis

Perform diagnostic paracentesis immediately to assess for spontaneous bacterial peritonitis (SBP) and determine serum-ascites albumin gradient 5, 6. Test for:

• Cell count with neutrophil count (>250 cells/µL indicates SBP)
• Gram stain and culture (inoculate 10 mL into blood culture bottles at bedside)
• Total protein and albumin concentration 5, 6

Medical Management

• Initiate sodium restriction (dietary counseling) plus diuretics - combination aldosterone antagonist (spironolactone) with loop diuretic (furosemide) is more effective than sequential therapy 5, 7
• For large-volume paracentesis (>5L removed), administer 20-25% IV albumin at 6-8 g per liter removed 5
• Given this patient's low albumin, elevated INR, and worsening renal function, consider albumin even for smaller volume removals 5

Renal Dysfunction Management

The increasing creatinine trend is particularly concerning and requires urgent assessment:

Determine Type of Acute Kidney Injury

• Rule out prerenal causes (volume depletion, diuretic overuse)
• Exclude intrinsic renal disease (urinalysis, urine sodium)
• If hepatorenal syndrome is suspected, initiate vasoconstrictors (terlipressin preferred) plus albumin 7

Monitoring Strategy

Test liver function every 1-3 months and measure HBV DNA by real-time PCR plus HBeAg status every 2-6 months during treatment 2.

Liver Transplantation Evaluation

All patients with decompensated cirrhosis should be evaluated for liver transplantation 1, 2. This is not optional - coordinate care with a transplant center immediately. The presence of ascites, low albumin, elevated INR, and worsening renal function indicates advanced liver failure with poor prognosis without transplantation.

Expected Outcomes with Antiviral Therapy

While antiviral therapy can improve liver function, Child-Pugh scores, and MELD scores in some patients 8, 2, 9, clinical improvement takes 3-6 months, and some patients with severely impaired liver function will not recover despite treatment 1. The 1-year transplant-free survival with entecavir in decompensated cirrhosis is approximately 87% 8, 2, but this patient's constellation of findings suggests advanced disease.

Critical Pitfalls to Avoid

1. Do not delay antiviral therapy waiting for HBV DNA quantification - any detectable level warrants immediate treatment 1
2. Never use interferon in decompensated cirrhosis - even small doses can precipitate liver failure 1, 2
3. Do not use lamivudine as first-line therapy due to high resistance rates that can cause clinical decompensation 3
4. Do not overlook coexistent liver disease - if ALT fails to normalize on antiviral therapy, consider NAFLD or other causes 10
5. Monitor for SBP vigilantly - infected patients with decompensated cirrhosis have 37.8% in-hospital mortality versus 3.2% in non-infected patients 11

Dyspnea Evaluation

The dyspnea may represent:

• Hepatic hydrothorax - perform therapeutic thoracentesis if present for symptom relief 5
• Restrictive ventilatory dysfunction from tense ascites
• Hepatopulmonary syndrome - requires specific evaluation

If hepatic hydrothorax with dyspnea/hypoxemia is confirmed, perform therapeutic thoracentesis immediately 5.